Evidence map›Paper›PMID 36699460›Full record

SynthesisFrontiers in genetics2022

Regulation of autophagy, lipid metabolism, and neurodegenerative pathology by heparan sulfate proteoglycans.

Nicholas Schultheis, Robert Becker, Gelila Berhanu, Alexander Kapral, Matthew Roseman, Shalini Shah, Alyssa Connell, Scott Selleck

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Gene Expression Dysregulation in Whole Blood of Patients withInternational journal of molecular sciences · 2024
    Article
  6. Sulfoglycodendron Antivirals with Scalable Architectures and Activities.Journal of chemical information and modeling · 2024
    Article
  7. Sulfoglycodendron Antivirals with Scalable Architectures and Activities.bioRxiv : the preprint server for biology · 2024
    Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Nicholas SchultheisDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States.
Robert BeckerDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States.
Gelila BerhanuDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States.
Alexander KapralDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States.
Matthew RosemanDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States.
Shalini ShahDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States.
Alyssa ConnellDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States.
Scott SelleckDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, United States.
Pennsylvania State University · USUniversity of Victoria · CA

Funding

Glysocaminoglycan Modifications as Regulators of Alzheimer's Disease-Related PathologiesR21AG070843 · NIA · PENNSYLVANIA STATE UNIVERSITY, THE · PI SELLECK, SCOTT B · 2021 to 2022
$435k
NIA NIH HHS R21 AG070843
6 · The paper itself

Abstract

Heparan sulfate modified proteins or proteoglycans (HSPGs) are an abundant class of cell surface and extracellular matrix molecules. They serve important co-receptor functions in the regulation of signaling as well as membrane trafficking. Many of these activities directly affect processes associated with neurodegeneration including uptake and export of Tau protein, disposition of Amyloid Precursor Protein-derived peptides, and regulation of autophagy. In this review we focus on the impact of HSPGs on autophagy, membrane trafficking, mitochondrial quality control and biogenesis, and lipid metabolism. Disruption of these processes are a hallmark of Alzheimer's disease (AD) and there is evidence that altering heparan sulfate structure and function could counter AD-associated pathological processes. Compromising presenilin function in several systems has provided instructive models for understanding the molecular and cellular underpinnings of AD. Disrupting presenilin function produces a constellation of cellular deficits including accumulation of lipid, disruption of autophagosome to lysosome traffic and reduction in mitochondrial size and number. Inhibition of heparan sulfate biosynthesis has opposing effects on all these cellular phenotypes, increasing mitochondrial size, stimulating autophagy flux to lysosomes, and reducing the level of intracellular lipid. These findings suggest a potential mechanism for countering pathology found in AD and related disorders by altering heparan sulfate structure and influencing cellular processes disrupted broadly in neurodegenerative disease. Vertebrate and invertebrate model systems, where the cellular machinery of autophagy and lipid metabolism are conserved, continue to provide important translational guideposts for designing interventions that address the root cause of neurodegenerative pathology.

Indexed as

autophagyco-receptorsheparan sulfatelipid metabolismmitochondrianicastrinpresenilinproteoglycans

Identifiers

PMID36699460
PMCPMC9870329
OpenAlexW4313893662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.